Takeda farms out cancer drug alisertib to Puma Biotech | pharmaphorum
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
Puma Biotechnology | Evaluate
After making $1M+ on illegal trades, former Puma Biotechnology executive gets prison term | Fierce Pharma
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology Inc
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Releases Updated Corporate Presentation
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top | Nasdaq
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
